FDA clears application for natural killer cell therapy to treat gastrointestinal cancers

FDA clears application for natural killer cell therapy to treat gastrointestinal cancers

The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.The clearance includes use of the investigational cell therapy in combination with chemotherapy, trastuzumab (Herceptin, Genentech) and pembrolizumab (Keytruda, Merck).CYNK-101 (Celularity) is a gene-edited, allogeneic natural killer (NK) cell therapy comprising human placental hematopoietic stem cells that are genetically modified to express high-affinity and cleavage-resistantRead More

Share on facebook
Share on twitter
Share on linkedin